This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: None, Subject name: Unknown
[{'content': 'Intracardiac defibrillator (ICD) is useful in which of the following ? \nSelect and explain. \nA. Person with Brugada, B. Person with Arrhythmogenic RV dysplasia, C. Person after acute MI with CAD, D. All of the above', 'role': 'user'}, {'content': 'Answer: D \nExplanation: Ref. AHA guidelines\n\xa0\nICD Indications (AHA Guidelines)\nClass I indications (ie, the benefit greatly outweighs the risk, and the treatment should be administered) are as follows:\n\nStructural heart disease, sustained VT\nSyncope of undetermined origin, inducible VT or VF at electrophysiologic study (EPS)\nLeft ventricular ejection fraction (LVEF) ≤35% due to prior MI, at least 40 days post-MI, NYHA class II or III\nLVEF ≤35%, NYHA class II or III\nLVEF ≤30% due to prior MI, at least 40 days post-MI\nLVEF ≤40% due to prior MI, inducible VT or VF at EPS\n\n\xa0\nClass IIa indications (ie, the benefit outweighs the risk and it is reasonable to administer the treatment) are as follows:\n\nUnexplained syncope, significant LV dysfunction, nonischemic cardiomyopathy\nSustained VT, normal or near-normal ventricular function\nHypertrophic cardiomyopathy with 1 or more major risk factors\nArrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) with 1 or more risk factors for sudden cardiac death (SCD)\nLong QT syndrome, syncope or VT while receiving beta-blockers\nNonhospitalized patients awaiting heart transplant\nBrugada syndrome, syncope or VT\nCatecholaminergic polymorphic VT, syncope or VT while receiving beta-blockers\nCardiac sarcoidosis, giant cell myocarditis, or Chagas disease', 'role': 'assistant'}]